Skip to main content
Fig. 5 | BMC Molecular Biology

Fig. 5

From: Myelodysplasia-associated mutations in serine/arginine-rich splicing factor SRSF2 lead to alternative splicing of CDC25C

Fig. 5

Drug-induced CDC25C alternative splicing. a Representative RT-PCR gel of alternative splicing of CDC25C in response to cisplatin treatment. (b to d) Line graph depicting average C5/C1 ratios for CDC25C in TF-1 TetON cells treated with b cisplatin, c CPT, and d TSA treated TF-1 TetON cells. Statistics are determined by two-way ANOVA with comparison to 0 µM (n = 4). e Western blot of HA-tagged protein, phosphorylated CHK2, phosphorylated p53, and GAPDH after no treatment (lane 1), 12 h 50 µM CIS (lane 2), 6 h 200 nM CPT (lane 3), 12 h 20 µM TSA (lane 4), or 48 h doxycycline treatment (lanes 5–9). Asterisks are p values as in Fig. 1

Back to article page